Filing Flows › ClearPoint Neuro (CLPT) › Guidance & outlook
ClearPoint Neuro (CLPT) guidance and outlook
ClearPoint Neuro (CLPT) lowered its guidance on Oct 28, 2026: Revenue $48.0M–$50.0M for FY2026; Revenue $634K for the quarter ending Sep 30, 2026; Revenue +100% for the quarter ending Sep 30, 2026.
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $48.0M–$50.0M | lowered |
| Revenue | the quarter ending Sep 30, 2026 | $634K | new |
| Revenue | the quarter ending Sep 30, 2026 | +100% | new |
From the earnings release filed Oct 28, 2026 (8-K on EDGAR).
ClearPoint Neuro's latest quarter
ClearPoint Neuro, Q3 2026: revenue $12.1M (+36% year over year), operating margin -52.4%, net loss $7.5M, operating cash flow −$5.1M. The chart follows the revenue to costs, profit and cash.
Questions
Did ClearPoint Neuro raise or lower its guidance?
ClearPoint Neuro (CLPT) lowered its guidance on Oct 28, 2026: Revenue $48.0M–$50.0M for FY2026; Revenue $634K for the quarter ending Sep 30, 2026; Revenue +100% for the quarter ending Sep 30, 2026.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.